"Designing Growth Strategies is in our DNA"

Middle East & Africa Insulin Pump Market Size, Share & COVID-19 Impact Analysis, By Product Type (Pumps [Tethered Pumps, Patch Pumps, and Others] and Consumables), By Disease Indication (Type 1 Diabetes and Type 2 Diabetes), By Distribution Channel (Hospital Pharmacy and Retail & Online Pharmacy), and Regional Forecast, 2023-2030

Last Updated: November 24, 2025 | Format: PDF | Report ID: FBI107535

 

KEY MARKET INSIGHTS

Play Audio Listen to Audio Version

The Middle East & Africa holds a substantial share in the global insulin pump market. The Middle East & Africa insulin pump market size is projected to record a CAGR of 15.2% during the forecast period. The global insulin pump market is projected to grow from USD 4.60 billion in 2022 to USD 15.51 billion by 2030.

The rising number of diabetes patients in the region and growing collaborations for R&D among major players to create new insulin delivery devices are boosting the regional market growth. According to the International Diabetes Federation (IDF) estimates, in 2021, about 73 million adults aged 20-79 years were suffering from diabetes in the Middle East & Africa region.

The report on the Middle East & Africa insulin pump market covers the following countries/regions – GCC, South Africa, and the Rest of the Middle East & Africa.

LATEST TRENDS

Rising Technological Advancements for Diabetes Therapy to Boost Industry Growth

The demand for type 1 diabetes therapy is increasing due to the rising incidence of this ailment across the Middle Eastern countries. Thus, healthcare centres are introducing technologically advanced devices for diabetes care to improve the delivery of quality healthcare services and clinical outcomes for patients. Such initiatives by healthcare agencies to boost the presence of new-generation pumps across the Middle East and Africa region are anticipated to propel the market growth.

  • According to a published article by the UAE Health Ministry in October 2021, the first artificial pancreatic system, MiniMed 780G, was installed at the HealthPlus Diabetes and Endocrinology Centre, which is part of United Eastern Medical Services (UEMedical) group and Mubadala Health.
  • In August 2021, the Emirates Health Services (EHS) revealed that the Al Qassimi Women’s & Children’s Hospital had successfully installed the first 'Medtronic Minimed 780G' in a patient with type 1 diabetes in the UAE.

DRIVING FACTORS

Increasing Initiatives for Awareness of Diabetes Management Devices to Augment Market Expansion

The prevalence of diabetes and its associated health complications is high across the region. Thus, several government and private agencies are initiating educational and awareness programs for the patient population regarding diabetes care and management. Moreover, strategic approaches by healthcare professionals across social platforms, such as mobile diabetes clinics, therapeutic nutrition, and education on type 1 and type 2 diabetes will increase awareness and adoption of these pumps, further boosting the market growth.

  • According to an article published by Arab News in November 2022, the Society of Diabetic Patient Friends in Jeddah launched educational and awareness programs to alert community members about the dangers of diabetes complications. With 126 awareness activities, the society assisted over 12,562 beneficiaries by offering check-ups, blood sugar analysis, free medical consultations, and free insulin pumps.

RESTRAINING FACTORS

Download Free sample to learn more about this report.

Limited Insulin Pump Awareness among Middle-Eastern Population to Hamper Market Growth

The demand for insulin and insulin delivery modalities among patients in middle and low-income countries is high. However, limited presence of insulin pumps, high product costs across these countries, and less developed healthcare facilities for diabetes management pose a barrier to accessing healthcare services for patients. Thus, lack of use of these pumps among diabetic patients and low regional awareness may further restrain the Middle East & Africa insulin pump market growth.

  • According to an article published by MDPI in November 2020, a cross-sectional study in Saudi Arabia showed that only 9% of children with type 1 diabetes used insulin pump therapy.

KEY INDUSTRY PLAYERS

The major players, such as Medtronic, F. Hoffmann-La Roche Ltd., and Tandem Diabetes Care, Inc. held a sizable Middle East & Africa insulin pump market share in 2022. The robust growth of these companies is attributable to extensive product offerings and enhanced distribution networks across the region.

Other prominent players, such as EOFLOW CO., LTD. and Terumo Corporation are focusing on inorganic strategies, such as partnerships and sales agreements to expand their distribution networks for diabetes care systems in the regional market. Also, rising authorizations for new products across Middle Eastern countries will further propel the market share of these companies.

  • In February 2023, EOFLOW CO., LTD. announced the launch of its tubeless, wearable, and disposable insulin pump, EOPatch, in the UAE.

LIST OF KEY COMPANIES PROFILED:

  • Medtronic (Ireland)
  • Tandem Diabetes Care, Inc. (U.S.)
  • Insulet Corporation (U.S.)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Terumo Corporation (Japan)
  • EOFLOW CO., LTD. (Korea)

KEY INDUSTRY DEVELOPMENTS:

  • March 2022: GulfDrug LLC, a pharmaceutical and medical device distribution company, entered into an agreement with EOFLOW CO., LTD. for the sales and distribution of EOFlow’s wearable insulin pump, EOPatch in the Middle East region.
  • March 2018: EOFLOW CO., LTD., a leading insulin pump provider, announced that it signed big-budget new contracts with several market players at the 43rd annual Arab Health Medical Expo.
  • April 2017: The Africa Diabetes Company launched a marketing campaign for Medtronic's insulin pump ‘MiniMed’ in Morocco, intending to serve the interests of its patients with diabetes.

REPORT COVERAGE

To gain extensive insights into the market, Download for Customization

The research report provides a detailed market analysis. It focuses on key aspects, such as the launch of new products, technological advancements, and the incidence of diabetes. Besides this, the report offers key insights into the latest market trends and highlights top industry developments, such as mergers, partnerships, and acquisitions, and effect of the COVID-19 pandemic on the market. In addition to the above-mentioned factors, the report encompasses several factors that have contributed to the market's growth in recent years.

Report Scope & Segmentation

  ATTRIBUTE

  DETAILS

Study Period

2019-2030

Base Year

2022

Estimated Year

2023

Forecast Period

2023-2030

Historical Period

2019-2021

Unit

Value (USD billion)

Growth Rate

CAGR of 15.2% from 2023-2030

Segmentation

Type; Diabetes Type; Distribution Channel; and Country/Sub-Region

By Type

  • Pumps
    • Tethered
    • Patch
    • Others
  • Consumables

By Diabetes Type

  • Diabetes 1
  • Diabetes 2

By Distribution Channel

  • Hospital Pharmacies
  • Retail & Online Pharmacies

 

By Country/ Sub-Region

  • GCC (By Diabetes Type)
  • South Africa (By Diabetes Type)
  • Rest of Middle East & Africa (By Diabetes Type)

 

 

 



Frequently Asked Questions

Registering a CAGR of 15.2%, the market will exhibit steady growth in the forecast period of 2023-2030.

The key factors driving the market are the rising diabetes care technologies across the region and growing patient awareness.

Medtronic and Insulet Corporation are the major players in the Middle East & Africa markets.

Seeking Comprehensive Intelligence on Different Markets?Get in Touch with Our Experts Speak to an Expert
  • 2019-2030
  • 2022
  • 2019-2021
  • 80
Download Free Sample

    man icon
    Mail icon
Growth Advisory Services
    How can we help you uncover new opportunities and scale faster?
Healthcare Clients
3M
Toshiba
Fresenius
Johnson
Siemens
Abbot
Allergan
American Medical Association
Becton, Dickinson and Company
Bristol-Myers Squibb Company
Henry Schein
Mckesson
Mindray
National Institutes of Health (NIH)
Nihon Kohden
Olympus
Quest Diagnostics
Sanofi
Smith & Nephew
Straumann